Telehealth and racial disparities in colorectal cancer screening: A pilot study of how virtual clinician characteristics influence screening intentions.
Cancer health disparities
colorectal cancer screening
precision prevention
telehealth
virtual human technology
Journal
Journal of clinical and translational science
ISSN: 2059-8661
Titre abrégé: J Clin Transl Sci
Pays: England
ID NLM: 101689953
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
11
2021
revised:
19
03
2022
accepted:
01
04
2022
entrez:
27
5
2022
pubmed:
28
5
2022
medline:
28
5
2022
Statut:
epublish
Résumé
Racial disparities in colorectal cancer (CRC) can be addressed through increased adherence to screening guidelines. In real-life encounters, patients may be more willing to follow screening recommendations delivered by a race concordant clinician. The growth of telehealth to deliver care provides an opportunity to explore whether these effects translate to a virtual setting. The primary purpose of this pilot study is to explore the relationships between virtual clinician (VC) characteristics and CRC screening intentions after engagement with a telehealth intervention leveraging technology to deliver tailored CRC prevention messaging. Using a posttest-only design with three factors (VC race-matching, VC gender, intervention type), participants ( The benefits of matching participants with a racially similar VC trended positive but did not reach statistical significance. Specifically, race-matching positively influenced screening intentions for Black participants but not for Whites ( To reduce racial CRC screening disparities, investments are needed to identify patient-focused interventions to address structural barriers to screening. This study suggests that telehealth interventions that match Black patients with a Black VC can enhance perceptions of credibility and message relevance, which may then improve screening intentions. Future research is needed to examine how to increase VC credibility and attractiveness, as well as message relevance without race-matching.
Identifiants
pubmed: 35619640
doi: 10.1017/cts.2022.386
pii: S2059866122003867
pmc: PMC9108377
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e48Subventions
Organisme : NCI NIH HHS
ID : T32 CA257923
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001427
Pays : United States
Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
No financial disclosures were reported by the authors of this paper.
Références
JMIR Hum Factors. 2019 May 08;6(2):e12700
pubmed: 31066688
Cancer. 2010 Feb 1;116(3):544-73
pubmed: 19998273
J Am Med Inform Assoc. 2020 Jun 1;27(6):957-962
pubmed: 32311034
Arch Fam Med. 2000 Nov-Dec;9(10):1156-63
pubmed: 11115223
J Natl Med Assoc. 2002 Aug;94(8):666-8
pubmed: 12152921
J Racial Ethn Health Disparities. 2019 Oct;6(5):1011-1020
pubmed: 31236800
J Racial Ethn Health Disparities. 2019 Oct;6(5):962-972
pubmed: 31119610
J Med Internet Res. 2017 May 09;19(5):e151
pubmed: 28487267
JAMA Health Forum. 2020 May;1(5):
pubmed: 34532717
Cancer Epidemiol Biomarkers Prev. 2012 May;21(5):728-36
pubmed: 22514249
Patient Educ Couns. 2011 Dec;85(3):e201-8
pubmed: 21840150
Ann Behav Med. 2012 Jun;43(3):372-82
pubmed: 22270266
Ann Fam Med. 2008 May-Jun;6(3):198-205
pubmed: 18474881
Ann Behav Med. 2017 Oct;51(5):694-706
pubmed: 28236077
Philos Trans R Soc Lond B Biol Sci. 2009 Dec 12;364(1535):3559-65
pubmed: 19884150
Prev Med Rep. 2019 May 15;15:100896
pubmed: 31193550
JAMA. 2021 May 18;325(19):1943-1945
pubmed: 34003238
J Health Soc Behav. 2002 Sep;43(3):296-306
pubmed: 12467254
N Engl J Med. 2017 Oct 19;377(16):1585-1592
pubmed: 29045204
Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2208-17
pubmed: 25368396
J Natl Cancer Inst. 2014 Apr;106(4):dju032
pubmed: 24681602
Psychooncology. 2015 Oct;24(10):1265-1278
pubmed: 26194469
J Commun. 2012 Oct;62(5):851-868
pubmed: 26405350
CA Cancer J Clin. 2020 May;70(3):145-164
pubmed: 32133645
Intell Virtual Agents. 2021 Jun;15(2):147-162
pubmed: 34027518
Cancer Epidemiol Biomarkers Prev. 2020 Apr;29(4):731-735
pubmed: 32066616
Am J Prev Med. 2021 Aug;61(2):251-255
pubmed: 33888362